Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study.


Journal

Journal of telemedicine and telecare
ISSN: 1758-1109
Titre abrégé: J Telemed Telecare
Pays: England
ID NLM: 9506702

Informations de publication

Date de publication:
Oct 2023
Historique:
medline: 25 9 2023
pubmed: 18 6 2021
entrez: 17 6 2021
Statut: ppublish

Résumé

Fatigue is one of the most frequent symptoms in anti-cancer immune therapy. Physical activity has been proven effective in reducing fatigue, but unmet needs remain regarding the provision and access to adapted programmes, which efficiently addresses the main barriers to PA. The PACTIMe-FEAS study primarily aimed at primarily to evaluate the feasibility and the acceptability of a videoconference-based 6-month programme promoting physical activity, and secondarily to assess its potential post-immediate and short-term effectiveness in reducing fatigue in cancer patients under immune therapy. Numeric self-reported questionnaires (Visual Analogue Scale-fatigue, Multidimensional Fatigue Inventory, International Physical Activity Questionnaire, Échelle de Motivation envers l'Activité Physique en contexte de Santé, Medical Outcomes Study 36-Item Short Form Health Survey, Hospital Anxiety and Depression Scale and Insomnia Severity Index) were completed by participants through an online secure platform at three time points: just before (T1), and after (T2) the programme, and 3 months later (T3). Sixteen participants (50% male, 50% female, mean age 54 years, 69% melanoma, 31% overweight), with moderate-to-severe fatigue, entered the internet-delivered intervention; 14 completed it, with an average completion rate of physical activity supervised sessions of 75%. Satisfaction was high, confirming a demand for group format, personalised approach, professional guidance and home-based device, to support the practice of regular physical activity. A decrease in fatigue was observed at the end of the programme. The recruitment process did prove to be challenging, with a relatively small eligible population, and will need to be reconsidered to envision a larger scale trial. But here and now, this feasibility study provides the first promising foundations to develop further research on the effectiveness of an original remote programme.

Identifiants

pubmed: 34137641
doi: 10.1177/1357633X211021743
doi:

Substances chimiques

Immune Checkpoint Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

716-724

Auteurs

Cécile Charles (C)

Gustave Roussy, Université Paris-Saclay, France.
Bordeaux Population Health Research Center (BPH- INSERM U1219), Methods for Intervention Research in Population Health (MéRISP), Bordeaux University, France.

Aurélie Bardet (A)

Gustave Roussy, Université Paris-Saclay, France.

Nusaïbah Ibrahimi (N)

Gustave Roussy, Université Paris-Saclay, France.

Olivier Aromatario (O)

Bordeaux Population Health Research Center (BPH- INSERM U1219), Methods for Intervention Research in Population Health (MéRISP), Bordeaux University, France.

Linda Cambon (L)

Bordeaux Population Health Research Center (BPH- INSERM U1219), Methods for Intervention Research in Population Health (MéRISP), Bordeaux University, France.

Alexis Imbert (A)

Gustave Roussy, Université Paris-Saclay, France.

Magali Pons (M)

Gustave Roussy, Université Paris-Saclay, France.

Bruno Raynard (B)

Gustave Roussy, Université Paris-Saclay, France.

Dominique Sauveplane (D)

Gustave Roussy, Université Paris-Saclay, France.

Camille Pouchepadass (C)

Gustave Roussy, Université Paris-Saclay, France.

Cédric Baudinet (C)

Mooven SAS, Research and Development Unit, Montpellier University, France.

Olivier Lambotte (O)

Clinical Immunology Department, AP-HP, Université Paris-Saclay, Hôpital Bicêtre, France.
Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, INSERM, CEA, France.

Aurélien Marabelle (A)

Drug Development Department, Gustave Roussy, Université Paris-Saclay, France.

Sarah Dauchy (S)

Gustave Roussy, Université Paris-Saclay, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH